替诺福韦治疗慢性乙型病毒性肝炎的优势特点及与其他常用核苷(酸)类似物的对比  

Compare the treatment advantages and features of Tenofovir and other nucleoside(acid) analogues in chronic hepatitis B

作　　者：韩杰[1] 田姗[1] 郝竟琳 陈倩[1] 张静姝[1] 朱姗薇[1] 

机构地区：[1]解放军第302医院,100039

出　　处：《首都食品与医药》2016年第8期66-70,共5页Capital Food Medicine

摘　　要：目的探讨研究替诺福韦治疗慢乙肝的疗效。方法从指南推荐、耐药性、患者耐受性及FDA妊娠用药分级等方面分析研究并与其他常用核苷(酸)类似物做对比。结果替诺福韦治疗慢乙肝各方面疗效显著,对比其他核苷(酸)类似物优势明显。结论替诺福韦是治疗慢乙肝患者的一线选择。Objective To investigate the treatment efficacy of Tenofovir in chronic hepatitis B Method Compare Tenofovir with other commonly used nucleoside（acid） analogues from guidelines recommendations, drug resistance, patient tolerance and FDA pregnancy drug classification etc. Results Comparing to other nucleoside（acid） analogues, Tenofovir has comprehensive significant effect and obvious advantages in treatment of chronic hepatitis B. Conclusion Tenofovir is the first treatment choice in chronic hepatitis B.

关 键 词：替诺福韦 慢性乙型病毒性肝炎 核苷(酸)类似物 

分 类 号：R512.62[医药卫生—内科学]